Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Insmed Incorporated (INSM)

20.37   1.25 (6.54%) 12-02 16:00
Open: 19 Pre. Close: 19.12
High: 20.43 Low: 18.9
Volume: 1,291,526 Market Cap: 2,760(M)

Technical analysis

as of: 2022-12-02 4:23:48 PM
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 23.86     One year: 27.87
Support: Support1: 18.23    Support2: 16.87
Resistance: Resistance1: 20.43    Resistance2: 23.86
Pivot: 18.79
Moving Average: MA(5): 18.91     MA(20): 18.75
MA(100): 22.03     MA(250): 22.48
MACD: MACD(12,26): -0.1     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 65     %D(3): 44.1
RSI: RSI(14): 61
52-week: High: 29.02  Low: 16.4
Average Vol(K): 3-Month: 1,411 (K)  10-Days: 1,271 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ INSM ] has closed above the upper band by 18.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 51% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.45 - 20.53 20.53 - 20.61
Low: 18.7 - 18.79 18.79 - 18.88
Close: 20.22 - 20.36 20.36 - 20.51

Company Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Headline News

Wed, 30 Nov 2022
Insmed To Present at the Nasdaq 47th Investor Conference -

Mon, 28 Nov 2022
Insmed (NASDAQ:INSM) Given New $38.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Tue, 22 Nov 2022
Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 7154 Shares of Stock - MarketBeat

Fri, 18 Nov 2022
BofA Securities Starts Insmed at Buy With $39 Price Target -

Fri, 18 Nov 2022
Bank of America Begins Coverage on Insmed (NASDAQ:INSM) - MarketBeat

Wed, 16 Nov 2022
Short Interest in Insmed Incorporated (NASDAQ:INSM) Declines By 10.3% - MarketBeat

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 135 (M)
Shares Float 134 (M)
% Held by Insiders 1.4 (%)
% Held by Institutions 97 (%)
Shares Short 7,760 (K)
Shares Short P.Month 8,610 (K)

Stock Financials

EPS -3.78
EPS Est Next Qtl -0.67
EPS Est This Year -2.71
EPS Est Next Year -2.28
Book Value (p.s.) -0.25
Profit Margin (%) -179.4
Operating Margin (%) -175.2
Return on Assets (ttm) -23
Return on Equity (ttm) -183
Qtrly Rev. Growth 44.9
Gross Profit (p.s.) 1.06
Sales Per Share 1.78
EBITDA (p.s.) -3.08
Qtrly Earnings Growth 0
Operating Cash Flow -381 (M)
Levered Free Cash Flow -185 (M)

Stock Valuations

PE Ratio -5.39
PEG Ratio 0
Price to Book value -81.49
Price to Sales 11.39
Price to Cash Flow -7.24

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.